Myxoid liposarcoma

Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

Retrieved on: 
Friday, October 13, 2023
Cancer, Lung cancer, Sarcoma, City of Hope National Medical Center, Drug, M.D, Plasma, Vomiting, Breast, AACR, PIN, CDK9, Safety, Half-life, Nausea, Therapy, RECIST, City, Neutropenia, Fatigue, KRON, Chordoma, Mechanism of action, SAN, Patient, Lung, Q&A, Neoplasm, PR, Cmax, Conference, Myxoid liposarcoma, Pharmaceutical industry

The preliminary analysis included 28 patients enrolled in a dose escalation study who received doses from 10 mg up to 60 mg (data cut-off September 1st, 2023).

Key Points: 
  • The preliminary analysis included 28 patients enrolled in a dose escalation study who received doses from 10 mg up to 60 mg (data cut-off September 1st, 2023).
  • KB-0742 also demonstrated dose proportional exposure and target engagement and a 24-hour plasma half-life, enabling intermittent dosing.
  • Because the maximum tolerated dose has not yet been identified, enrollment in the dose escalation portion continues and dosing of patients at the 80 mg dose level is underway.
  • “These positive preliminary efficacy and safety data underscore the promise of KB-0742 to treat patients with transcriptionally addicted tumors.

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Retrieved on: 
Tuesday, October 18, 2022
LinkedIn, Physician, U.S. Securities and Exchange Commission, SEC, Bone, Life, Effectiveness, IND, Review, ASCO, Myxoid liposarcoma, Protocol, Ewing's sarcoma, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sarcoma, Patient, Drug development, Biology, Hematological Cancer Research Investment and Education Act, Investor, Annual report, Twitter, Research, Cyclophosphamide, Cancer, Research institute, Private Securities Litigation Reform Act, Food, Trial of the century, Food and Drug Administration, Safety, Letter, GLOBE, Clinical trial, MD Anderson Cancer Center, Topotecan, Death, SUSAR, FDA, Pharmaceutical industry, Medical imaging, Salinicola salarius

The pause in new patient enrollment is due to a metastatic FET-rearranged sarcoma patient death that was classified as a suspected unexpected serious adverse reaction (SUSAR).

Key Points: 
  • The pause in new patient enrollment is due to a metastatic FET-rearranged sarcoma patient death that was classified as a suspected unexpected serious adverse reaction (SUSAR).
  • Salarius continues to plan to release interim sarcoma clinical trial results later this year.
  • Salarius believes data released during ASCO 2021 demonstrated synergy in a Ewing sarcoma cell line when seclidemstat was used in combination with these agents.
  • Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and certain additional sarcomas that share a similar biology, also referred to as Ewing-related or FET-rearranged sarcomas.